Oragenics Inc. Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
TL;DR
Oragenics secures $16.5 million through a public offering, offering investors a chance to benefit from its innovative intranasal therapeutics for neurological disorders.
Oragenics raised $16.5 million by selling 660,000 units of Series H Convertible Preferred Stock and Warrants at $25.00 per unit, funding clinical development and operations.
Oragenics' funding advances the development of ONP-002 for concussion, promising a future with better treatments for neurological disorders and improved patient outcomes.
Discover how Oragenics is pioneering intranasal therapeutics for concussions and neurological disorders, with a recent $16.5 million boost to fuel groundbreaking research.
Found this article helpful?
Share it with your network and spread the knowledge!
Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company specializing in intranasal therapeutics for neurological disorders, has announced the successful closure of its public offering of Series H Convertible Preferred Stock and Warrants. The company raised approximately $16.5 million in gross proceeds from the sale of 660,000 units, each priced at $25.00. Each unit consists of one share of Series H Convertible Preferred Stock and one Warrant, which is immediately exercisable at the same price, potentially bringing in an additional $16.5 million if fully exercised.
The net proceeds from this offering are earmarked for several critical areas. Primarily, the funds will support the clinical development of ONP-002, Oragenics' innovative intranasal therapy aimed at treating concussions. Additionally, a portion of the proceeds will be used to repay a $3 million bridge note, with the remainder allocated towards research and development efforts and general operational expenses. Dawson James Securities served as the sole placement agent for this offering.
This financial milestone is a testament to Oragenics' commitment to advancing treatments for neurological disorders, particularly mild traumatic brain injury (mTBI), commonly known as concussion. The development of ONP-002 represents a promising avenue for addressing the unmet medical needs of individuals suffering from concussions, offering potential benefits in terms of efficacy and ease of administration through its intranasal delivery system.
The successful funding round not only underscores the investor confidence in Oragenics' scientific approach and business strategy but also highlights the growing interest in innovative therapies for neurological conditions. As the company moves forward with the clinical development of ONP-002, the healthcare and investment communities will be watching closely for the potential impacts on concussion treatment paradigms and patient outcomes.
Curated from InvestorBrandNetwork (IBN)
